Phase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254( )

BACKGROUND: GSK3640254 (GSK’254) is a next-generation human immunodeficiency virus type 1 (HIV-1) maturation inhibitor with pharmacokinetics (PK) supporting once-daily therapy. METHODS: This phase IIa double-blind (sponsor-unblinded), randomized, placebo-controlled, adaptive study evaluated antivira...

Descripción completa

Detalles Bibliográficos
Autores principales: Spinner, Christoph D, Felizarta, Franco, Rizzardini, Giuliano, Philibert, Patrick, Mitha, Essack, Domingo, Pere, Stephan, Christoph J, DeGrosky, Michelle, Bainbridge, Veronica, Zhan, Joyce, Dumitrescu, Teodora Pene, Jeffrey, Jerry L, Xu, Jianfeng, Halliday, Fiona, Gan, Jianjun, Johnson, Mark, Gartland, Martin, Joshi, Samit R, Lataillade, Max
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9536290/
https://www.ncbi.nlm.nih.gov/pubmed/34996113
http://dx.doi.org/10.1093/cid/ciab1065

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9536290/
https://www.ncbi.nlm.nih.gov/pubmed/34996113
http://dx.doi.org/10.1093/cid/ciab1065

Ejemplares similares